
Please try another search
Per Reuters, Ryanair Holdings plc (NASDAQ:RYAAY) plans to reduce flights to and from Italy by 25% following a significant drop in bookings in the region due to the coronavirus outbreak.
Capacity in the airline’s primary market, Italy, will be slashed for the period between Mar 17 and Apr 8. This European low-cost carrier witnessed a dramatic fall in ticket purchases over the past week and a "significant step up" passenger no-shows, especially from and within Italy.
However, Ryanair does not expect its flight cancellations to have as much of an impact on its current financial year ending Mar 31. As far as the virus’ impact on its next year ’s results is concerned, the carrier feels that it is "far too early to speculate".
In the wake of the virus outbreak, which caused a slowdown in air travel demand, Ryanair’s rivals British Airways and easyjet plc also announced flight cancellations.
Recently, U.S. airline American Airlines Group (NASDAQ:AAL) also suspended all flights to Milan from the United States citing a drop in demand. The airline suspended Milan flights from New York (JFK) and Miami through April 24.
Latin American carrier LATAM Airlines Group (NYSE:LTM) also announced its decision to cancel flights from Sao Paulo to Milan through Apr 16 on the same grounds.
Zacks Rank & Another Key Pick
Ryanair sports a Zacks Rank #1 (Strong Buy). Another top-ranked stock in the same space is Controladora Vuela Compania de Aviacion, S.A.B. de C.V (NYSE:VLRS) , which carries the same Zacks Rank as Ryanair. You can see the complete list of today’s Zacks #1 Rank stocks here.
Shares of Controladora Vuela have rallied more than 23% in a year’s time.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Through many years of frustration among gold bugs due to the failure of gold stock prices to leverage the gold prices in a positive way, there were very clear reasons for that...
I know there is the smell of fear in the air when I see my readership double as we reach a point where weekly chart factors come into play. Up until last week, markets have...
Professional traders get paid because of one skill and one skill only: the ability to foresee what the world (or the economy, at least) might look like in six to nine months....
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.